EGFR and neoplasm: We designed a highly sensitive, specific, reproducible test that detects mutations in exons 18, 19, 20, and 21 in tumor samples from patients with NSCLC to identify individuals who are most likely to respond to EGFR TKI therapy using one 5-micron tissue section.